Nymox Pharmaceutical (NASDAQ:NYMX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMXGet Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Shares of NYMX opened at $1.30 on Tuesday. Nymox Pharmaceutical has a one year low of $0.94 and a one year high of $2.87. The company has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $1.54. The firm has a market capitalization of $117.36 million, a PE ratio of -8.67 and a beta of 1.12.

A number of institutional investors and hedge funds have recently modified their holdings of NYMX. Advisor Group Holdings Inc. lifted its holdings in Nymox Pharmaceutical by 365.4% in the third quarter. Advisor Group Holdings Inc. now owns 12,100 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 9,500 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Nymox Pharmaceutical by 71.0% in the second quarter. Goldman Sachs Group Inc. now owns 48,736 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 20,236 shares during the period. Geode Capital Management LLC lifted its holdings in Nymox Pharmaceutical by 21.8% in the third quarter. Geode Capital Management LLC now owns 50,731 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 9,086 shares during the period. Morgan Stanley lifted its holdings in shares of Nymox Pharmaceutical by 15.9% during the second quarter. Morgan Stanley now owns 76,239 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 10,471 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Nymox Pharmaceutical by 1,834.9% during the second quarter. Millennium Management LLC now owns 323,364 shares of the biopharmaceutical company’s stock valued at $511,000 after purchasing an additional 306,652 shares during the last quarter. Institutional investors and hedge funds own 1.59% of the company’s stock.

About Nymox Pharmaceutical (Get Rating)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.

Recommended Stories

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.